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Abstract An important risk gene in schizophrenia is
D-amino acid oxidase (DAAO). To establish if expression
of DAAO is altered in cortical, hippocampal or thalamic
regions of schizophrenia patients, we measured gene
expression of DAAO in a post-mortem study of elderly
patients with schizophrenia and non-affected controls in
both hemispheres differentiating between gray and white
matter. We compared cerebral post-mortem samples
(granular frontal cortex BA9, middle frontal cortex BA46,
superior temporal cortex BA22, entorhinal cortex BA28,
sensoric cortex BA1–3, hippocampus (CA4), mediodorsal
nucleus of the thalamus) from 10 schizophrenia patients to
13 normal subjects investigating gene expression of DAAO
in the gray and white matter of both hemispheres of the
above-mentioned brain regions by in situ-hybridization.
We found increased expression of DAAO-mRNA in the
hippocampal CA4 of schizophrenic patients. Compared to
the control group, both hemispheres of the hippocampus of
schizophrenic patients showed an increased expression of
46% (right, P = 0.013) and 54% (left, P = 0.019),
respectively. None of the other regions examined showed
statistically significant differences in DAAO expression.
This post-mortem study demonstrated increased gene
expression of DAAO in the left and right hippocampus of
schizophrenia patients. This increased expression could be
responsible for a decrease in local D-serine levels leading to
a NMDA-receptor hypofunction that is hypothesized to
play a major role in the pathophysiology of schizophrenia.
However, our study group was small and results should be
verified using larger samples.
Keywords DAAO  Gene expression  Schizophrenia 
In situ hybridization  Hippocampus
Introduction
Schizophrenia is a complex neurodevelopmental disorder
(Weinberger 1987; Lewis and Levitt 2002), in which sus-
ceptibility genes are assumed to play a specific role in the
pathophysiology of the disease via abnormal synaptic con-
nectivity (Harrison 1999). Genome wide scanning and
mapping of regions associated with risk for schizophrenia
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led to the detection of several hypothetical susceptibility
genes, including D-amino acid oxidase (DAAO) (Chumakov
et al. 2002; Schumacher et al. 2004) in addition to a number
of established risk genes. These genes encode proteins
involved in processes beginning with brain development to
the maintenance of glutamatergic transmission in the adult
brain. DAAO is involved in the N-methyl-D-aspartate
receptor (NMDAR) hypofunction that is hypothesized to
play a major role in the pathophysiology of schizophrenia
(Coyle 1996). D-Serine, an allosteric activator of the
NMDA-type glutamate receptor (NMDAR) in the brain
(Schell et al. 1995), is degraded by DAAO. Accordingly,
increased DAAO levels might lead to NMDAR dysfunction
via decreased serine levels (Kapoor et al. 2006; Bendikov
et al. 2007). DAAO itself is a peroxisomal homodimeric
flavoenzyme showing the characteristics of the dehydroge-
nase-oxidase class of flavoproteins with a low kinetic effi-
ciency (Molla et al. 2006). DAAO catalyzes the oxidative
deamination of D-amino acids, with the exception of
D-aspartate and D-glutamate, which are oxidized by
D-aspartate oxidase (DASPO) (Sacchi et al. 2002). Endo-
genous D-serine is synthesized from L-serine by serine
racemase (Wolosker et al. 1999), and is degraded by DAAO,
which specifically oxidizes D-amino acids (Horiike et al.
1994; Schell et al. 1995).
The DAAO risk gene has been shown to be associated
with schizophrenia (Chumakov et al. 2002; Liu et al. 2004;
Schumacher et al. 2004; Corvin et al. 2007; Wood et al.
2007). While the influence of a single risk gene is con-
sidered rather small, the coherent influence of multiple
susceptibility genes is said to contribute significantly to the
risk of developing schizophrenia in either an epistatic or a
polygenic mode (Harrison and Weinberger 2005). Li and
He (2007) performed a meta-analysis combining all case–
control and family-based association studies published
until October 2005 that involve 16 polymorphisms,
including those assessing the genes of D-amino acid oxi-
dase (DAAO) activator (DAOA or G72; located on chro-
mosome 13q32–34) and DAAO (located on chromosome
12q24). Although previous studies have reported strong
associations in allelic, genotypic or haplotypic analyses,
the results of the presented meta-analysis provided only
weak evidence for an association between DAOA/DAAO
genes and schizophrenia. Another meta-analysis on DAOA
by Detera-Wadleigh and McMahon (2006) presented
highly significant evidence of an association between
nucleotide variations in the DAOA/DAAO region and
schizophrenia. It is interesting to note that the alleles and
haplotypes were not identical across the studies—some of
them were located 50 kb telomeric of DAOA (Detera-
Wadleigh and McMahon 2006). However, there were no
real genotypes available, which prevented comparison of
haplotype frequencies. Association tests with DAAO, made
by Goldberg et al. (2006) were consistently non-significant.
They performed two family-based association studies of
various single nucleotide polymorphisms in the gene for
DAAO. The latest meta-analysis was carried out by Shi
et al. (2008) and combined 18 associating studies con-
ducted before April 2007 involving 15 single nucleotide
polymorphisms. Of these, two showed an association with
schizophrenia in Asians while one was found to be asso-
ciated with the disorder in Europeans.
While no single marker showed evidence of an overall
association with bipolar disorder (Schumacher et al. 2004)
several authors hypothesized that DAOA and DAAO might
also contribute to bipolar affective disorder, because link-
age findings in the chromosomal regions of DAOA and
DAAO had similarly been discovered for bipolar disorder
(Dawson et al. 1995; Jones and Tarrant 1999; Kelsoe et al.
2001). Additionally, the psychopathological characteristics
shared by both schizophrenia and bipolar disorder, leading
to the assumption of a commonly shared etiology, also
underscore this hypothesis.
In order to emphasize the linkage between DAAO and
schizophrenia in a severely affected subpopulation of
schizophrenia patients, we investigated gene expression of
DAAO in several human brain regions [granular frontal
cortex (BA9), middle frontal cortex (BA46), superior
temporal cortex (BA22), the entorhinal cortex (BA28),
sensoric cortex (BA1–3), the hippocampus (CA4) and the
mediodorsal nucleus of the thalamus] by in situ-hybrid-
ization. We determined mRNA levels in the right and left
hemisphere of schizophrenia patients versus healthy sub-
jects, respectively. So far, it is known that DAAO-mRNA
is localized in astrocytes (Yang et al. 2005). Due to the cell
specific expression of DAAO in varying cell populations,
we chose to analyze gray and white matter in BA9, BA46,
BA22, BA28 and BA1–3 separately. We hypothesized a
differential expression of DAAO in key regions of
schizophrenia pathophysiology, namely the hippocampus
CA4. Schizophrenia is not a uniform disease. Instead, it
could best be characterized as a syndrome with the dif-
ferent courses of the disease being associated with different
neurobiological backgrounds, i.e. first episode versus
patients with a chronic course of the disease. Accordingly,
we tried to measure DAAO gene expression in the brains of
a severely affected subgroup whose patients were thought
to have had a similar course of schizophrenia.
Materials and methods
Human post-mortem tissue
We collected post-mortem brain samples from patients
with DSM-IV residual schizophrenia (n = 10) and
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elderly comparison subjects (n = 13) who had been
diagnosed using the DSM-IV checklist of the American
Psychiatric Association (APA). Due to incomplete col-
lection of the hippocampus, number of investigated cases
ranged from 8 (right hemisphere) up to 10 (left hemi-
sphere) in schizophrenia patients and 10 (right hemi-
sphere) up to 13 (left hemisphere) in healthy probands.
All schizophrenia patients had been long-term inpatients
at the State Mental Hospital Wiesloch, Germany and had
been diagnosed ante-mortem according to DSM IV cri-
teria (American PA, 1994). After assessing patients’
history of antipsychotic treatment by examining their
medical charts, we then calculated the last dose as well
as the cumulative dose during the last 10 years of anti-
psychotic medication in chlorpromazine equivalents
(CPE) through the algorithm developed by Jahn and
Mussgay (1989). Table 1 outlines the demographic
variables. Controls were collected at the Institutes of
Neuropathology, of the Universities of Heidelberg and
Bonn and the respective clinical records obtained from
their relatives and general practitioners. All assessments
and post-mortem evaluations and procedures had been
approved by the Ethics Committees of the Faculties of
Medicine of Heidelberg and Bonn Universities,
Germany.
All patients and controls underwent thorough neuropa-
thologic characterization in order to rule out associated
neurovascular or neurodegenerative disorders, such as
Alzheimer‘s disease and multi-infarct dementia (Braak and
Braak 1991; Braak et al. 2006). The staging according to
Braak was 2 or less for all subjects. Patients and normal
comparison subjects had no history of alcohol, drug abuse,
or severe physical illness as for example carcinoma. Nor-
mal comparison subjects had no history of psychiatric
disorders. All patients had been receiving long-term anti-
psychotic medication before death, such as clozapine
(n = 3), zotepine (n = 1), olanzapine (n = 2), flupen-
thixole (n = 1), haloperidol (n = 3), perphenazine
(n = 1), pipamperone (n = 1), promethazine (n = 1),
zuclopenthixole (n = 1), perazine (n = 1), prothipendyl
(n = 1).
Post-mortem brains were dissected at the midline of the
hemispheres. Tissue blocks were prepared from the gran-
ular frontal cortex (BA9), the middle frontal cortex
(BA46), the superior temporal cortex (BA22), the entorh-
inal cortex (BA28), the sensoric cortex (BA1–3), the hip-
pocampus cornu ammonis 4 (CA4), and the mediodorsal
nucleus of the thalamus from the right and left hemisphere.
Blocks were immediately snap-frozen in liquid nitrogen-
cooled isopentane and stored at -80C. From these, 10 lm
Table 1 Characteristics of post-mortem samples from patients with schizophrenia and normal comparison subjects
Characteristic Tissue from
patients with
schizophrenia
(n = 10)
Tissue from
normal patient
subjects
(n = 13)
Subjects gender
(N)
10 13
Male 5 11
Female 5 2
Mean SD Mean SD
Age at death (years) 69.10 14.40 64.54 13.58
Postmortem interval (h) 21.00 10.66 23.85 23.12
pH 6.42 0.35 6.65 0.37
Age at onset (years) 24.60 7.36
Duration of disease (years) 43.20 11.57
Duration of hospitalization (years) 25.10 15.32
Duration of antipsychotic medication (years) 35.00 9.72
Last dose of antipsychotic medication in
chlorpromazine equivalents (CPE in g)
686.26 787.36
Cumulative dose (last 10 years) of antipsychotic
medication in chlorpromazine equivalents (CPE in kg)
4.36 3.19
There were no statistically significant differences between age at time of death, post-mortem interval (PMI) and brain pH. Schizophrenia patients
were characterized by duration of disease, duration of medication and medication (last dose) in chlorpromazine equivalents (CPE), as well as
cumulative dose over the last ten years in CPE
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sections were cut and were collected on coated slides. All
material was coded and experiments were carried out by
researchers who were blind to diagnosis.
In situ-hybridization
In situ-hybridization (Zink et al. 2005) was performed on
two sections of each brain region with 35S-UTP-labeled
cRNA-probes of the DAAO gene. RNA from human
cerebral cortex (RNeasy, Qiagen, Hilden, Germany) was
reverse transcribed with the reverse transcriptase Super-
script II (Gibco Life-Technologies, Karlsruhe, Germany)
and the oligo-dT-Primers (Perkin–Elmer, Wellesley,
USA). After PCR-amplification (Promega, Mannheim,
Germany) with specific primers derived from DAAO
(bases 251–710 in Genbank NM 001917) the amplicons
were subcloned into gGEM-T vector (Promega, Mann-
heim, Germany). Correct amplification and orientation
were checked by commercial sequencing (MWG,
Ebersberg, Germany). Linearized plasmids were tran-
scribed in vitro with Sp6 or T7-RNA-polymerase (MBI-
Fermentas, St Leon Roth, Germany). Efficiency of
incorporation of radioactively labeled [35S]-UTP was
measured and hybridizations with antisense- and sense-
probes using concentration of 107 cpm/ml were carried
out under high stringency conditions (55C, 50% form-
amide) for 16 h. Hybridizations with sense-probes were
intended as negative controls for specificity. After sev-
eral washing steps including RNAse A-digestion, slices
were dehydrated and were exposed to X-ray films
(Biomax MR1 18 9 24 cm) for 2–6 days.
Image analysis
Autoradiographic films (see representative examples of
the hippocampus in Fig. 1) were analyzed with a video
camera (Sony XC ST 70) and the AIS software (Applied
Information Systems, Chapel Hill, USA). Non-specific
signals were assessed separately for each section in the
white matter separating hippocampal CA4 and cerebral
cortex. These readings were subtracted from gray values
in the regions of interest (total binding) resulting in a
semiquantitative determination of mRNA-abundance.
Gray value images of the co-exposed 14C-calibration
standards (Amersham, Buckinghamshire, UK) were used
to compute a calibration curve by non-linear least
squares fitting, which defined the relationship between
gray values and concentration of radioactivity.
We measured DAAO specific bindings in the cortical
brain regions in both gray and white matter. In the hip-
pocampus, the region of interest was the CA4 region. In the
thalamus, we investigated the mediodorsal nucleus. Both
regions were selected due to their impact in the
pathophysiology of schizophrenia (Schmitt et al. 2009;
Carlsson et al. 1999).
Statistical analysis
Statistical analyses were performed with SPSS 15. All tests
were two-tailed. The level of significance was defined as
P \ 0.05. Distributions for all dependent variables were
examined in both groups using histograms and the Kol-
mogorov–Smirnov test on normality. Due to our small
sample size, the power for the Kolmogorov–Smirnov test
was not very high. Nonetheless, our results suggest a nor-
mal distribution of the data and analysis by parametric
tests.
In all regions analyzed, we first performed oneway
analyses of variance (ANOVA) with diagnostic group as
independent factor. Additionally, we assessed correlations
between the dependent and intervening variables age, PMI,
brain pH, disease duration, dose, and duration of medica-
tion using Spearmen rank correlation coefficients, as some
of the intervening variables like PMI and medication dose
deviated significantly from normal distribution. These
correlations were computed separately for schizophrenia
patients and—if present—for controls. In all regions,
oneway ANOVA with factor gender was calculated to
analyze if specific bindings differed between male and
female subjects. As in these initial analyses, age and PMI
showed a significant influence on specific bindings in the
hippocampal region, we performed analyses of covariance
(ANCOVA) with diagnostic group as independent factor
and age and PMI as covariates.
This is an explorative study aimed at finding variables
that may show differences in the expression of DAAO-
mRNA between schizophrenia patients and control sub-
jects. If a Bonferroni adjustment of the error probability of
CA3
 DG
DG
CA3
CA4
CA4
1 2 
Fig. 1 Gene expression of DAAO in the hippocampus expressed as
Bq/g brain tissue in the gray matter of the right and left hemisphere.
Compared to the control group, we found a statistically significant
increase in the expression of 46% (P = 0.013) in the right and of 54%
(P = 0.019) in the left hemisphere of the hippocampal CA4 of
schizophrenic patients
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first kind for the number of statistical tests was applied, no
significant differences between schizophrenia patients and
controls would remain. However, one must keep in mind
that adjustment of the error probability would decrease the
power of the test to such an extent that the power of
detecting existing mean differences would be very low.
Thus, the present results are presented without error
probability correction. Due to our explorative study design
and the problems of multiple testing, these findings offer no
conclusive evidence for a causal relationship. An inde-
pendent larger sample has to be analyzed in an effort to
confirm the positive findings of this study.
Results
Descriptives for specific bindings in the analyzed regions are
shown in Table 2. In the present study, the hippocampal CA4
of schizophrenia patients revealed a significant increased
expression of DAAO-mRNA in both hemispheres. Com-
pared to the control group, we noted a 46% increase in
expression (F = 6.5; df = 1,10; P = 0.029) in the right
CA4 of schizophrenia patients (Fig. 1) and an increase of
54% of DAAO-mRNA in the left CA4 (F = 5.8; df = 1,9;
P = 0.039) in ANOVA (Fig. 2). Schizophrenia patients did
not differ from controls in terms of age (F = 0.6; df = 1,21;
P = 0.45), pH (F = 0.5; df = 1,20, P = 0.68), PMI
(F = 0.1; df = 1,21; P = 0.72) or gender (v2 = 3.20;
df = 1; P = 0.074).
In all other regions assessed [the granular frontal cortex
(BA9), the middle frontal cortex (BA46), the superior tem-
poral cortex (BA22), the entorhinal cortex (BA28), the
sensoric cortex (BA1–3), and the mediodorsal nucleus of the
thalamus], we saw no statistically significant differences in
the expression of DAAO. Overall, in controls, the medio-
dorsal nucleus of the thalamus and CA4 of the hippocampus
showed the least expression, while the cortical regions BA46
and 28 showed the highest level of expression (Table 2).
In schizophrenic patients, we noted significant correla-
tions between specific bindings and age (rho = 0.94,
P = 0.005) in the left hippocampus along with significant
correlations between specific bindings and PMI
(rho = 0.90, P = 0.037) in the right hippocampus. Spe-
cific binding of DAAO in the hippocampus did not show
any significant influences of gender or brain pH.
From analysis of covariance (ANCOVA, factor diag-
nosis, covariates age, PMI) intending to adjust the analysis
on diagnostic effects for these intervening variables, the
noted increase in DAAO-mRNA expression in schizo-
phrenic patients was still significant in both the right
(F = 11.1, df = 1, 8, P = 0.013) and the left (F = 9.3,
df = 1, 7, P = 0.019) hippocampal CA4 (Fig. 2).
Furthermore, schizophrenic patients showed significant
correlations between specific bindings and disease duration
(rho = 0.83, P = 0.042) as well as duration of medication
(rho = 0.83, P = 0.042) in the left CA4. However, cor-
relations of last dose and cumulative dose (last 10 years)
with DAAO expression levels were not significant.
Discussion
To the best of our knowledge, the present post-mortem
investigation is the first study showing increased gene
Table 2 Descriptive Statistics for specific bindings (mean ± standard deviation) expressed in Bq/g brain tissue in the analyzed brain regions in
schizophrenic patients and controls
Region Left hemisphere Right hemisphere
Control Schizophrenia Control Schizophrenia
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
BA9 granular frontal cortex (white matter) 579 ± 215 595 ± 174 837 ± 85 594 ± 252
BA9 granular frontal cortex (gray matter) 452 ± 190 428 ± 145 494 ± 172 437 ± 181
BA46 middle frontal cortex (white matter) 692 ± 0 745 ± 138 717 ± 0 691 ± 230
BA46 middle frontal cortex (gray matter) 466 ± 159 573 ± 125 572 ± 207 549 ± 191
BA22 superior temporal cortex (white matter) 527 ± 0 523 ± 63 696 ± 259 475 ± 72
BA22 superior temporal cortex (gray matter) 418 ± 152 644 ± 297 551 ± 192 549 ± 199
BA1–3 sensoric cortex (white matter) 471 ± 187 597 ± 155 621 ± 280 549 ± 224
BA1–3 sensoric cortex (gray matter) 410 ± 179 491 ± 234 476 ± 191 438 ± 185
Hippocampus (CA4) 401 ± 42 619 ± 197* 353 ± 84 515 ± 137*
BA28 entorhinal cortex (white matter) 624 ± 281 724 ± 206 740 ± 302 499 ± 379
BA28 entorhinal cortex (gray matter) 559 ± 234 582 ± 248 556 ± 243 550 ± 265
Thalamus (mediodorsal nucleus) 424 ± 115 450 ± 156 369 ± 84 363 ± 157
Significant differences have been detected in hippocampal CA4 (*P \ 0.05)
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expression of DAAO in the left and right hippocampus
(CA4) of schizophrenia patients compared to healthy sub-
jects. Concerning mRNA levels, Kapoor et al. (2006)
determined the presence of DAAO in human brain tissues
from schizophrenic and normal individuals via RT–PCR.
They found the relative expression of DAAO-mRNA to be
higher in the cerebellum than in the parietal cortex and
cerebellar mRNA levels that were significantly higher in
schizophrenia patients versus controls. Additionally, they
explored DAAO activity in both regions by a colorimetric
method (Kapoor et al. 2006) showing that DAAO activity
was significantly higher in the cerebellum of schizophrenic
patients and undetectable in the human parietal cortex.
Bendikov et al. (2007) monitored DAAO protein levels in
post-mortem frontal cortex and hippocampus by Western-
blot analysis, finding no significant differences in schizo-
phrenia patients. They did note, however, that hippocampal
DAAO levels correlated significantly with the duration of
disease. This is in line with our findings of a significant
correlation between DAAO expression and the duration of
disease as well as duration of medication in the left hip-
pocampus. As age, disease duration, and duration of
medication are dependent, the respective correlations may
be related to each other.
It must be kept in mind that the present study only
measured DAAO expression in a chronic subgroup of
schizophrenia patients, as we wanted to assess effects in the
most severely affected subgroup in the schizophrenia
syndrome. If we had included patients with shorter disease
durations, it is possible that our findings would not persist.
Madeira et al. (2008) demonstrated an increase in DAAO
activity in the parietal cortex of schizophrenic patients.
They also found that the group of individuals with a history
of antipsychotic drug use showed significantly higher
DAAO activity when compared to individuals with no
history. The first group included all schizophrenic patients
and a subset of patients suffering bipolar disorder. Both
psychotic disorders share many features and several
authors argue that the illnesses could represent a continuum
of symptoms. However, they did not investigate patients of
the same diagnostic group without antipsychotics and with
antipsychotic treatment, rendering comparisons of treat-
ment effects difficult.
While Verrall et al. (2006) discovered a statistically
significant increase in the expression of DAAO-mRNA in
the cerebellum of schizophrenic patients, but their immu-
nohistochemical studies only showed a trend of the protein
level in this direction. In our study, we did not investigate
the cerebellum. However, in line with our findings, they
reported no differential expression of DAAO in the
DLPFC. In this region, Verrall et al. also found a statisti-
cally significant increase in the expression of the serine
racemase, an enzyme of the synthesis of D-serine, further
supporting other disturbances of the D-serine pathway in
schizophrenia.
The increased expression of DAAO in both sides of the
hippocampus could be responsible for a decrease in hip-
pocampal D-serine (Bendikov et al. 2007; Hashimoto et al.
2003, Hashimoto et al. 2005), leading to a NMDA receptor
hypofunction that is thought to occur in schizophrenia
(Coyle 1996; Chumakov et al. 2002). By detecting statis-
tically significant increases in DAAO expression values
only in the hippocampus and not in any other brain region,
alterations of DAAO expression in schizophrenia seem to
be region-specific.
In our study, we investigated Cornu ammonis (CA4) of
the left and right hippocampus. Previously, we reported
decreased numbers of oligodendrocytes in the left and right
hippocampus (CA4) of schizophrenic patients, showing the
impact of this region in the pathophysiology of schizo-
phrenia (Schmitt et al. 2009). Among hippocampal sub-
fields, CA4 is the deep polymorph layer of the dentate
expression of DAAO in the hippocamus
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Fig. 2 Exemplary X-ray film
analysis obtained from the
computer program AIS
(Analytical Imaging Station
from Interfocus). The intensity
of the 35[S]-isotope was
measured in Bq/g brain tissue.
On the slides (1 left hemisphere,
2 right hemisphere) we marked
our region of interest CA4
(rectangle) and the subregions
CA3 and the dentate gyrus (DG)
1662 G. Habl et al.
123
gyrus and receives collateral mossy fibers from the gran-
ulate cells (Amaral and Lavanex 2007). CA4 is among the
regions hypothesized to be strongly involved in distur-
bances of connectivity in schizophrenia (Harrison and
Eastwood 2001).
The hippocampus plays an important role in memory
consolidation as well as the transfer of memory contents
from short-term to long-term memory, and disturbances of
verbal memory have been detected in schizophrenia
(Heckers and Konradi 2002). Structural magnetic reso-
nance imaging and post-mortem studies in schizophrenia
have shown volume loss in the medial temporal region,
especially in the hippocampus, as one of the most consis-
tent structural abnormalities (Heckers 2001).
Additionally, post-mortem studies have shown volume
loss in hippocampal subregions in schizophrenia, which
may be related to positive symptoms (Bogerts et al. 1990,
1993; Bogerts 1997).
A new approach regarding pharmacological treatment of
schizophrenia is an in vitro and in vivo trial with a selective
DAAO inhibitor (Adage et al. 2008). A pharmaceutical
product based on selective DAAO inhibitors was not only
able to increase D-serine fraction in rat cortex and mid-
brain, but also had a normalizing effect on phencyclidine
(PCP)-induced prepulse inhibition and hyperlocomotion in
mice. The mechanism of action of this inhibitor is the
increase of D-serine levels by preventing the oxidation of
D-serine via DAAO. D-serine is an endogenous full agonist
at the glycine site of the NMDA-receptor. By increasing
the bioavailability of D-serine, one should consequently
achieve enhanced NMDA neurotransmission leading to
potential anti-psychotic activities. This new therapeutic
approach shows the importance of better insight into the
DAAO/D-serine/glycine equilibrium, which should be
investigated in large studies to assess and provide proof for
new therapy options through modification of the respective
equilibrium.
In summary, we detected increased gene expression of
DAAO in the left and right hippocampus (CA4) of
schizophrenia patients compared to a healthy comparison
group. These alterations may be related to the pathophys-
iology of schizophrenia, such as the hypoglutamatergic
state with NMDA receptor hypofunction, the GABAergic
deficit as well as migrational and myelination disturbances.
However, our study also entails some limitations. First, our
finding of increased bindings in the left and right hippo-
campus might not hold up, if a more stringent statistical
analysis adjusting of the first kind error probability for the
number of investigated regions was applied. Keeping this
in mind, the results of this explorative study should be
interpreted with caution, until they are confirmed on a
larger independent sample. Especially, in the right hippo-
campus, we investigated only a low number of cases.
In this post-mortem study, all patients had been treated
with typical or atypical neuroleptics over decades, so that one
might speculate that antipsychotic treatment itself may have
influenced our results. However, as there was no correlation
with the cumulative or last dose of antipsychotics in CPE and
DAAO expression, we suggest no strong influence of anti-
psychotic treatment on our results. To gain additional insight
animal studies investigating the influence of neuroleptics on
DAAO expression are warranted. Furthermore, since many
findings in post-mortem tissue are not specific for schizo-
phrenia, psychiatric patients with other diagnoses such as
bipolar disorder should be investigated to show disease-
specific effects on DAAO expression. Moreover, since we
did not investigate protein levels of DAAO isoforms, it is not
entirely clear, if changes in the level of the mRNA transcript
also reflect changes in protein levels, which again limits our
conclusions. Further, post-mortem studies should investigate
DAAO and D-serine activity as well as expression of NMDA
receptor subunits in the hippocampus to determine whether
the change in mRNA results in a functional outcome.
Additional investigations are required to clarify the influence
of the DAAO gene on the expression of mRNA and protein
level, and to identify at-risk polymorphisms within the
DAAO and DAOA gene associated with a risk for
schizophrenia.
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